ISPOR 2024

Join EVERSANA and global healthcare leaders as they convene at ISPOR 2024, the leading global conference for Health Economics and Outcomes Research (HEOR).

Our Value & Evidence and Data & Analytics experts will be onsite to discuss how we use a variety of analytics, evidence generation, and evidence synthesis activities to help support market access and reimbursement for pharmaceutical and medical devices.

Schedule a meeting with one of our experts to discuss your business needs and visit us in Booth #400.

EVERSANA’s 2024 Poster Presentations

We are proud to present several posters at this year’s ISPOR conference.

Monday, May 6, 2024 | Poster Session 1 

• C017: Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Immuno-oncology (IO) for First-Line (1L) Esophageal Squamous Cell Carcinoma (ESCC) in Adult Patients
  Smyth E¹, Sibiga A², Coaquira Castro J³, Szafranski K², Craigie S², Zhan L^{3
  1}Oxford University Hospitals NHS Foundation Trust, Oxford, UK, ²EVERSANA, Burlington, ON, Canada, ³BeiGene USA, Inc., Emeryville, CA, USA
• C017: MSR19: Methods for Relaxing the Proportional Odds Assumption in Meta-analysis of Aggregate Data
  Disher T
  EVERSANA, West Porters Lake, NS, Canada

Monday, May 6, 2024 | Poster Session 2 

• EE116: Budget Impact Model Framework of Positron Emission Tomography Compared to Single Photon Emission Computed Tomography Myocardial Perfusion Imaging for Coronary Artery Disease Diagnosis
  Walczyk Mooradally A¹, Priest S¹, Ferko N¹, Szabo E², Cabra HA^{3
  1}EVERSANA, Burlington, ON, Canada, ²GE HealthCare, Pittsburgh, PA, USA, ³GE HealthCare, Miami, FL, USA

Tuesday, May 7, 2024 | Poster Session 3 

• EE225: Economic Modeling of Topical and Systemic Treatments for Atopic Dermatitis: A Structured Literature Review
  Silverberg J¹, Stephenson B², Yim C³, Lewis J³, Almuallem L⁴, Cohen L⁴, Persaud E⁴, Singh S^{4
  1}George Washington University School of Medicine and Health Sciences, Washington, DC, USA, ²Arcutis Biotherapeutics, Inc, San Francisco, CA, USA, ³Arcutis Biotherapeutics, Inc, Maple, ON, Canada, ⁴EVERSANA, Burlington, ON, Canada
• EE296: A United States Payer Budget Impact Analysis of Myocardial Perfusion Imaging Modalities Positron Emission Tomography with Flurpiridaz Compared to Single Photon Emission Computed Tomography in Coronary Artery Disease Diagnosis
  Priest S¹, Walczyk Mooradally A¹, Ferko N¹, Szabo E², Cabra HA^{3
  1}EVERSANA, Burlington, ON, Canada, ²GE HealthCare, Pittsburgh, PA, USA, ³GE HealthCare, Miami, FL, USA
• HSD67: A Retrospective Study Assessing Clinical and Economic Impacts of a Multidisciplinary Approach for Reducing Risk of Catheter-Related Thrombosis in a U.S. Health System
  Zazyczny KA¹, Alsbrooks K², Bryson B³, Hartner K¹, Plank J¹, Griffin A^{4
  1}Bryn Mawr Hospital, Bryn Mawr, PA, USA, ²Becton Dickinson and Company, Salt Lake City, UT, USA, ³Paoli Hospital, Paoli, PA, USA, ⁴EVERSANA, Halifax, NS, Canada

Tuesday, May 7, 2024 | Poster Session 4 

• MSR81: Quantitative Assessment of Effect Modifiers in NMA – Leveraging Subgroup Data
  Disher T
  EVERSANA, West Porters Lake, NS, Canada
• EE375: Cost Savings and the Opportunity for Expanded Treatment Access with Increased Use of Biosimilar Adalimumab in the United States
  Shastri K¹, Clarke K², Ainslie-Garcia M³, Ferko NS^{3
  1}Fresenius Kabi SwissBioSim GmbH, Morris Plains, NJ, USA, ²EVERSANA, Brampton, Canada, ³EVERSANA, Burlington, ON, Canada

Wednesday, May 8, 2024 | Poster Session 5 

• EE434: Benefits of a Polymer Tip in Torsional Phacoemulsification: A Targeted Literature Search and Budget Impact Model
  Hsiao CW¹, Wright G², Son D², Pan LC^{3
  1}Alcon Inc., Fort Worth, TX, USA, ²EVERSANA, Burlington, ON, Canada, ³Alcon Vision LLC, Fort Worth, TX, USA
• MSR104: Use of Stochastic Search Variable Selection for Dimension Reduction in Large NMAs
  Disher T
  EVERSANA, Burlington, ON, Canada